{
  "id": 16052793,
  "title": "Govt unveils new guidelines for safer drug prescriptions",
  "url": "https://urgent.news/2026/10/22/govt-unveils-new-guidelines-for-safer-drug-prescriptions",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T13:50:50.000Z",
  "source": {
    "name": "Live Mint",
    "slug": "live-mint",
    "url": "https://www.livemint.com/news/drug-prescriptions-pharma-use-health-ministry-ipc-11792668660806.html"
  },
  "original_language": "en",
  "account": "New Delhi: In an effort to reduce overprescribing and improper use of medicines, the health ministry, along with the Indian Pharmacopoeia Commission, has unveiled new guidelines for the National Formulary of India (2026). The guidelines aim to ensure safer and more appropriate treatments without limiting doctors' clinical judgment. They cover essential treatments like antibiotics, pain relievers, government-cleared drugs, generic substitutes, and emergency stockpiled medications. Prior to these guidelines, the focus was on academic dosages and safety details, but now they serve as a reference for appropriate prescribing, dispensing, and administration of medicines. The guidelines are advisory, and doctors' professional clinical judgment and existing regulations remain the primary consideration. The expert panel that selects therapies considers factors such as clinical urgency, state licensing approvals, and generic access through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana. The IPC document emphasizes that medicine monographs and formulation strengths are based on medical literature, regulatory approvals, national programs, and expert inputs. Doctors and pharmacists should use the guidelines to make informed decisions about safe dosages, formulations, and appropriate therapies. The guidelines are periodically reviewed and updated to remain clinically relevant.",
  "summary": "New criteria for India’s 2026 National Formulary will guide medicine selection using essential-medicine lists, national programmes, regulatory approvals, pharmacopoeia standards and expert recommendations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}